Aquestive Therapeutics, Inc.

NasdaqGM:AQST Voorraadrapport

Marktkapitalisatie: US$426.2m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Aquestive Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Aquestive Therapeutics' is Dan Barber, benoemd in May2022, heeft een ambtstermijn van 2.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.50M, bestaande uit 24% salaris en 76% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.52% van de aandelen van het bedrijf, ter waarde $ 6.89M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.2 jaar en 2.3 jaar.

Belangrijke informatie

Dan Barber

Algemeen directeur

US$2.5m

Totale compensatie

Percentage CEO-salaris24.0%
Dienstverband CEO2.4yrs
Eigendom CEO1.5%
Management gemiddelde ambtstermijn2.2yrs
Gemiddelde ambtstermijn bestuur2.3yrs

Recente managementupdates

Recent updates

Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Sep 07
Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

Aug 20

Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

Aug 11
Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Jul 24
What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

May 22
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

Apr 09

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 28
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1

Jan 19

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Jan 05
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction

Oct 11

Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film

Sep 28

Aquestive Therapeutics: FDA Stymies Libervant Launch

Sep 05

Aquestive Therapeutics: A First Take

Aug 29

Analyse CEO-vergoeding

Hoe is Dan Barber's beloning veranderd ten opzichte van Aquestive Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$29m

Dec 31 2023US$2mUS$600k

-US$8m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$542k

-US$54m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$1mUS$424k

-US$71m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$840kUS$410k

-US$56m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$50m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$1mUS$389k

-US$66m

Sep 30 2019n/an/a

-US$68m

Jun 30 2019n/an/a

-US$64m

Mar 31 2019n/an/a

-US$80m

Dec 31 2018US$2mUS$319k

-US$61m

Sep 30 2018n/an/a

-US$61m

Jun 30 2018n/an/a

-US$38m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$899kUS$300k

-US$14m

Compensatie versus markt: De totale vergoeding ($USD 2.50M ) Dan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).

Compensatie versus inkomsten: De vergoeding van Dan is gestegen terwijl het bedrijf verliesgevend is.

CEO

Dan Barber (48 yo)

2.4yrs

Tenure

US$2,496,141

Compensatie

Mr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 unti...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Daniel Barber
CEO, President & Director2.4yrsUS$2.50m1.52%
$ 6.5m
A. Toth
Chief Financial Officer3.8yrsUS$1.12m0.43%
$ 1.8m
Lori Braender
General Counsel6.1yrsUS$1.19m0.52%
$ 2.2m
Cassie Jung
Chief Operating Officer1.9yrsgeen gegevens0.26%
$ 1.1m
Alexander Schobel
Chief Innovation & Technology Officer9.8yrsUS$810.02k1.08%
$ 4.6m
Stephen Wargacki
Chief Science Officerno datageen gegevens0.28%
$ 1.2m
Sherry Korczynski
Senior Vice President of Sales & Marketingless than a yeargeen gegevens0.027%
$ 117.0k
Peter Boyd
Senior Vice President of Information Technology & Human Resources1.6yrsgeen gegevens0.26%
$ 1.1m
Gary Slatko
Chief Medical Officerno datageen gegevensgeen gegevens
Carl Kraus
Chief Medical Officer1.3yrsgeen gegevens0.28%
$ 1.2m
Robert Arnold
VP of Financeno datageen gegevensgeen gegevens

2.2yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AQST wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Daniel Barber
CEO, President & Director2.4yrsUS$2.50m1.52%
$ 6.5m
Santo Costa
Independent Director8.8yrsUS$202.16k0.019%
$ 81.1k
Timothy Morris
Independent Director2.2yrsUS$145.23k0%
$ 0
Gregory Brown
Independent Chairman of the Board17.6yrsUS$150.77k0.082%
$ 351.4k
Julie Krop
Independent Director3.7yrsUS$137.69k0%
$ 0
John Cochran
Independent Vice Chairman of the Board20.8yrsUS$137.23k0.11%
$ 465.6k
Marco Taglietti
Independent Director3.7yrsUS$121.78k0%
$ 0
Carlos Camargo
Member of Scientific Advisory Board2.1yrsgeen gegevensgeen gegevens
Ruchi Gupta
Member of Scientific Advisory Board2.1yrsgeen gegevensgeen gegevens
David Bernstein
Member of Scientific Advisory Board2.1yrsgeen gegevensgeen gegevens
David Fleischer
Member of Scientific Advisory Board2.1yrsgeen gegevensgeen gegevens
Matthew Greenhawt
Member of Scientific Advisory Board2.1yrsgeen gegevensgeen gegevens

2.3yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AQST wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.